drug · antibody
relatlimab
Phase 2updated 6mo agoby Bristol-Myers Squibb Co🔗 ChEMBL
Phase 2community read0 votes
🐶 often sniffed alongside
top 6Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for melanoma and 13 investigational indications.
indications
indications
NSCLCColorectal CancerDLBCL
targets
Lymphocyte activation gene 3 protein
all catalysts(0)
nothing on the calendar yet
Trials studying relatlimab
- phase3A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
- phase2Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis
- phase2A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
- phase3A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- phase2Pan Tumor Rollover Study
- phase2Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
- phase2Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- phase3VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
News(1)
- Dr Sznol on Optimal Treatment Sequencing in MelanomaMario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.onclive · 6mo ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that